Advertisement
Advertisement
PCRX
Pacira BioSciences, Inc. Common Stock
22.63
USDSponsored
-0.02
-0.09%
Mar 24, 12:14 UTC -4
Open
PCRX Earnings Reports
Positive Surprise Ratio
PCRX beat 26 of 41 last estimates.
63%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$181.89M
/$0.59
Implied change from Q4 25 (Revenue/ EPS)
-7.61%
/+5.36%
Implied change from Q1 25 (Revenue/ EPS)
+7.68%
/-4.84%
Pacira BioSciences, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, PCRX reported earnings of 0.56 USD per share (EPS) for Q4 25, missing the estimate of 0.92 USD, resulting in a -38.21% surprise. Revenue reached 196.87 million, compared to an expected 204.43 million, with a -3.70% difference. The market reacted with a -9.57% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.59 USD, with revenue projected to reach 181.89 million USD, implying an increase of 5.36% EPS, and decrease of -7.61% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
XOMA Royalty Corporation Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.15
Actual
$0.12
Surprise
+175.90%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Mar 20, 2026 For Q4 25
Estimate
-$0.16
Actual
-$0.16
Surprise
+1.96%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
Abivax SA - ADR
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.52
Actual
-$1.02
Surprise
+32.82%
FAQ
What were Pacira BioSciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Pacira BioSciences, Inc. Common Stock reported EPS of $0.56, missing estimates by -38.21%, and revenue of $196.87M, -3.7% below expectations.
How did the market react to Pacira BioSciences, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -9.57%, changed from $26.02 before the earnings release to $23.53 the day after.
When is Pacira BioSciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Pacira BioSciences, Inc. Common Stock's next earnings report?
Based on 5
analysts, Pacira BioSciences, Inc. Common Stock is expected to report EPS of $0.59 and revenue of $181.89M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement